格隆汇12月17日丨南京熊猫(600775.SH)在投资者互动平台表示，公司参与了江苏省重点研发计划专项 中关于脑机接口项目的课题。目前，公司尚未产生这方面的销售收入。 ...

格隆汇12月17日丨南京熊猫(600775.SH)在投资者互动平台表示，公司参与了江苏省重点研发计划专项 中关于脑机接口项目的课题。目前，公司尚未产生这方面的销售收入。 ...

Core Insights - The article highlights the top and bottom AH share premium rates as of December 15, with Northeast Electric (00042) leading at a premium of 900.00% and CATL (03750) at the bottom with a premium of -11.03% [1][2][3] Premium Rate Rankings - The top three AH stocks by premium rate are: - Northeast Electric (00042) with a premium of 900.00% and a deviation value of 26.91% [1][2] - Beijing Capital Machinery (00187) with a premium of 266.67% and a deviation value of 27.25% [1][2] - Hongye Futures (03678) with a premium of 265.78% and a deviation value of -3.92% [1][2] - The bottom three AH stocks by premium rate are: - CATL (03750) with a premium of -11.03% and a deviation value of -2.28% [1][3] - China Merchants Bank (03968) with a premium of -0.77% and a deviation value of -0.05% [1][3] - Heng Rui Medicine (01276) with a premium of 1.62% and a deviation value of -1.73% [1][3] Deviation Value Rankings - The top three AH stocks by deviation value are: - Beijing Capital Machinery (00187) with a deviation value of 27.25% [1][4] - Northeast Electric (00042) with a deviation value of 26.91% [1][4] - Hongxing Meikailong (01528) with a deviation value of 18.57% [1][4] - The bottom three AH stocks by deviation value are: - GAC Group (02238) with a deviation value of -19.95% [1][5] - First Tractor Company (00038) with a deviation value of -16.78% [1][5] - Longyuan Power (00916) with a deviation value of -13.18% [1][5]

Core Viewpoint - The company is currently in a concentrated delivery period at the end of the year and is organizing production and delivery according to customer requirements [1] Group 1 - The company, Nanjing Panda, is actively responding to investor inquiries on its interactive platform [1] - The current phase involves significant production and delivery activities aligned with client demands [1]

Core Viewpoint - The ongoing legal dispute involves investors and Nanjing Panda Electronics Co., Ltd. regarding false statements in securities, with potential compensation for affected investors [1][2][4]. Group 1: Company Performance and Disclosures - On January 30, 2024, Nanjing Panda announced an estimated net profit for 2023 of approximately CNY 16.19 million to CNY 24.29 million, with a net profit excluding non-recurring gains and losses estimated between CNY -3.27 million to CNY 4.82 million [1][4]. - However, the actual net profit reported on March 29, 2024, was CNY -237.86 million, and the net profit excluding non-recurring gains and losses was CNY -257.01 million, indicating a significant discrepancy between the forecast and actual results [1][4]. Group 2: Legal Implications and Investor Rights - According to new judicial interpretations regarding false statements in securities, investors who suffered losses due to Nanjing Panda's alleged false disclosures can file lawsuits for compensation, which may include losses from price differences, commissions, and stamp duty [2][4]. - Investors who purchased Nanjing Panda shares between January 31, 2024, and March 28, 2024, and held them until the market close on March 28, 2024, are eligible to seek compensation, with the amount to be determined by the court [2][4].

Group 1 - The 2025 Brain-Computer Interface Conference will be held in Shanghai from December 4 to 5, focusing on the theme "Connecting Minds, Innovating Shanghai" [3] - The conference will feature a main forum, eight sub-forums, a product launch, a developer forum, and four competitions to showcase the latest advancements and application prospects in brain-computer interface technology [3] - The conference venue is located in the Minhang District's New Hongqiao International Medical Center, near Fudan University Huashan Hospital, leveraging clinical resources for development [3] Group 2 - The conference aims to establish Shanghai as a global hub for brain-computer interface innovation and industry development, supported by the local government and the Shanghai Municipal Science and Technology Commission [3] - Significant clinical trials related to brain-computer interfaces have been initiated, including the first domestic implantable brain-computer interface GCP clinical trial and the first real-time Chinese language decoding IIT trial [4] - These advancements have garnered attention from prestigious international journals such as Nature and MIT Technology Review, highlighting the global interest in the developments [4]

Core Viewpoint - Nanjing Panda Electronics (600775) shares increased nearly 7%, reaching HKD 4.86 with a trading volume of HKD 71.7075 million, driven by news related to the upcoming 2025 Brain-Computer Interface Conference in Shanghai [1] Group 1: Event Overview - The Shanghai Municipal Science and Technology Commission held a press conference for the 2025 Brain-Computer Interface Conference on December 1 [1] - The conference will take place from December 4 to 5, themed "Connecting the Brain World, Intelligence Gathering in Shanghai," featuring one main forum, eight sub-forums, one product launch, one developer forum, and four competitions [1] Group 2: Industry Development - The conference will showcase the latest advancements and application prospects in brain-computer interface technology [1] - The event is set in the "Brain Intelligence Land" future industry cluster area, located in the Minhang District near Fudan University Huashan Hospital [1] - The local government and the Shanghai Municipal Science and Technology Commission are establishing platforms for concept validation, testing certification, and pilot processing to attract top domestic and international teams and companies [1] Group 3: Clinical Trials and Research - The first domestic implantable brain-computer interface GCP clinical trial and several pioneering trials in real-time Chinese language decoding and invasive brain-computer interface systems have been initiated [1] - These advancements have garnered significant attention from international journals such as Nature and MIT Technology Review [1]

Core Viewpoint - The brain-computer interface concept has seen significant market activity, with notable stock price increases among related companies on December 5th [1][2] Group 1: Stock Performance - Nanjing Panda reached its daily limit up, indicating strong investor interest [1][2] - Dineike experienced a nearly 10% increase in stock price, reflecting positive market sentiment [1][2] - Other companies in the sector, including Beiyikang, Innovation Medical, Chengyitong, and Aipeng Medical, also saw their stock prices rise [1][2]

Core Viewpoint - Nanjing Panda Electronics Co., Ltd. (00553) experienced a nearly 7% increase in stock price, reaching 4.86 HKD with a trading volume of 71.7075 million HKD, following news related to the upcoming 2025 Brain-Computer Interface Conference in Shanghai [1]. Group 1: Event Overview - The Shanghai Municipal Science and Technology Commission held a press conference on December 1 for the 2025 Brain-Computer Interface Conference, scheduled for December 4-5, themed "Brain Link World · Intelligent Shanghai" [1]. - The conference will feature one main forum, eight sub-forums, one product launch, one developer forum, and four competitions, showcasing the latest advancements and application prospects in brain-computer interface technology [1]. Group 2: Industry Development - The conference will take place in the "Brain Intelligence World" future industry cluster area located in the Minhang District, near Fudan University Huashan Hospital [1]. - The local government and the Shanghai Municipal Science and Technology Commission are establishing platforms for concept validation, testing certification, and pilot processing to attract outstanding domestic and international teams and companies, aiming to make Shanghai a global hub for brain-computer interface innovation [1]. Group 3: Clinical Trials and Research - The first domestic implantable brain-computer interface GCP clinical trial, the world's first real-time Chinese language decoding IIT trial, the first domestic cerebrospinal interface IIT trial, and the first domestic invasive brain-computer interface system prospective clinical trial have been initiated, receiving significant attention from international journals such as Nature and MIT Technology Review [1].

Core Viewpoint - The A-share market is experiencing a surge in the brain-computer interface (BCI) concept, with notable stock increases among several companies following the 2025 Brain-Computer Interface Conference held in Shanghai from December 4 to 5 [1] Company Performance - Dineike (狄耐克) saw its stock price increase by over 14% [1] - Nanjing Panda (南京熊猫) reached the daily limit with a 10% increase [1] - Other companies such as Chengyitong (诚益通), Innovation Medical (创新医疗), Sanbo Brain Science (三博脑科), and Aipeng Medical (爱朋医疗) also experienced stock price increases [1]